Blogs - Medconnect

Home >>

	Cardiology
	Endocrinology
	Oncology
	Psychiatry

SPECIALTIES

	Allergy & Immunology
	Dermatology
	Emergency Medicine
	Gastroenterology
	General Medicine
	Geriatrics
	Infectious Diseases
	Nephrology
	Neurology
	Ob/Gyn & Women's Health
	Ophthalmology
	Orthopaedics
	Otolaryngology
	Paediatrics
	Pain & Anaesthesia
	Pulmonology
	Rheumatology
	Sports Medicine
	Surgery
	Urology

Cardiac Conversations

Rohan Jayasinghe, FRACP, earned his MBBS with Class 1 Honours from Sydney University and has a PhD in Cardiovascular Research from University of New South Wales. He completed his Interventional Cardiology Fellowship at Beth Israel Hospital in New York City and is currently the Director of Cardiovascular Services and Cardiology at the Gold Coast Hospital and Professor of Cardiology at Griffith University and Professor of Medicine at Bond University. Rohan's current clinical interests include coronary interventions, interventions of structural heart disease, heart failure and risk factor modification. His current research interests include cardiovascular genetics, multi-centre clinical trials and interventional device innovations.

Lyse or not to lyse?

By Rohan on 11/3/2009 11:43 AM

Thromoblysis was thought to be a thing of the past for the busy metropolitan hospitals when the interventional cardiologists embraced the primary angioplasty as the therapy of choice for those presenting with acute ST elevation myocardial infractions.

Climate change may be good for your heart: controversial. But it could be true?

By Rohan on 7/14/2009 1:34 PM

There is a significant amount of buzz about climate change in the media lately. The leaders at the G8 summit were hotly debating the means of reducing green house gas emissions with medium term targets that served nothing but lip service from most quarters. There is only guarded optimism on any breakthrough at the Copenhagen summit on climate change planned for the end of the year.

All about macho baldies, Atkins diet, Rosi and the heart!

By Rohan on 6/23/2009 10:37 AM

There have been some very interesting developments in the world of cardiology over the last few weeks. Adding a new spin to the debate over the cardiovascular safety of the potent diabetic medication Rosiglitazone (Rosi), the RECORD trial data were released. The new data testify to the safety of Rosiglitazone disputing the controversial meta-analysis that incriminated the agent in 2007. According to RECORD data adverse cardiac events rate with Rosi is no different to that of metformin or suphonylureas.

Strict blood sugar control in diabetes: evidence not so sweet?

By Rohan on 5/21/2009 11:23 AM

Diabetes mellitus remains a major health problem with a prevalence of 8-16% among the population aged between 55-85 years. There is convincing evidence to prove the benefits of good glycaemia control to prevent end organ damage related to microvascular complications...

Research funding - can the industry compromise integrity?

By Rohan on 5/4/2009 1:45 PM

The recent news headlines related to the unrestricted academic grant made by the pharmaceutical company Sanofi Aventis to Baker IDI research institute in Melbourne has given rise to some controversy and contention.

Yes, you can have that chocolate!

By Rohan on 4/24/2009 3:25 PM

Well, there is emerging sweet news about chocolate that would justify the guilty indulgence of us chocoholics and give the poetic connection between the heart and chocolates a more scientific outlook...

SYNTAX

By Rohan on 3/26/2009 10:06 AM

The landmark SYNTAX trial results were released late last year and published recently. The issue of CABG Vs Stenting for patients with left main stem stenosis or triple vessel disease has been debated for a long time and different trials have shed different light into this. SYNTAX is a some what large RCT that looked into this issue from a drug eluting stent era perspective.